Schizophrenia
Treatment
Antipsychotic medication is the foundation of schizophrenia treatment. The difference between adequate care and excellent care is in which agent is chosen, what gets monitored, and what happens when side effects show up — because “it's working, tolerate the rest” is not a treatment plan.
What is schizophrenia?
Schizophrenia is a serious mental illness involving disruptions in thought, perception, emotional expression, motivation, and cognition. It is not a split personality and it is not rare in the sense people assume — NIMH puts U.S. prevalence estimates in the range of 0.25% to 0.64%, which is hundreds of thousands of American adults.
Symptoms are usually grouped into three domains. Positive symptoms — hallucinations, delusions, disorganized speech — are what most people picture, and they are also what antipsychotic medication addresses most reliably. Negative symptoms such as reduced motivation, blunted emotional expression, and social withdrawal respond less predictably, and cognitive symptoms affecting attention, working memory, and planning are frequently the biggest obstacle to work and independent living. A treatment plan that only tracks the positive symptoms is measuring the easy third.
Onset is typically late teens through early thirties, often earlier in men. The length of time psychosis goes untreated matters: shorter duration of untreated psychosis is associated with better outcomes, which is why an early, accurate evaluation carries real weight rather than being a formality.
Dr. Farkas completed psychiatric residency at one of only four NIH-designated research centers for schizophrenia in the country, holds a PhD in neuroscience alongside her MD, and brings a pharmaceutical research background to antipsychotic selection and management. That is the level of expertise usually found at an academic medical center rather than in community psychiatry.
Symptom domains
Domains and criteria as described in the DSM-5-TR. This page is educational and is not a diagnostic tool.
How Dr. Farkas treats schizophrenia
Sophisticated antipsychotic management with the monitoring that's supposed to accompany it. The plan follows your history and response — not a protocol template.
What to expect from your first appointment
A new patient evaluation with Dr. Farkas runs 30–60 minutes. It covers your psychiatric and medical history, every antipsychotic tried with dose and duration, what each one did for symptoms, and what it cost you in side effects. That medication history is what determines whether the next step is a different agent, a long-acting formulation, or a clozapine discussion.
With your consent, a family member is welcome to attend. You'll leave with a diagnosis explained in plain terms, a treatment plan you understand and agree with, and a follow-up already scheduled. Telehealth is available throughout South Carolina and New York. In-person appointments are available at the Hilton Head Island, SC office.
Related Conditions
Call or text 988 (Suicide & Crisis Lifeline). Text HOME to 741741 for the Crisis Text Line. Call 911 or go to your nearest emergency room if you or someone you care about is in immediate danger.
Medical disclaimer: This page is for educational purposes and does not constitute medical advice. No doctor–patient relationship is established through website use. Individual results vary; no specific outcome is guaranteed. Telehealth visits are conducted on a HIPAA-compliant platform. Gabriella I. Farkas, MD PhD, is a board-certified psychiatrist licensed in South Carolina and New York.
Ready for expert review
of your treatment plan?
30–60 minutes. Research-center-level antipsychotic expertise. Monitoring that doesn't treat side effects as the cost of doing business.
Schizophrenia treatment centers on antipsychotic medication — second-generation agents (aripiprazole, olanzapine, risperidone, cariprazine, lurasidone) are typically first-line. Long-acting injectable formulations reduce relapse in patients with adherence difficulty. Clozapine is uniquely effective for treatment-resistant schizophrenia. Dr. Farkas trained at an NIH-designated schizophrenia research center and contributed to cariprazine development.
Key Takeaways
- Schizophrenia affects thinking, perception, emotional expression, motivation, and cognition. It isn't a split personality.
- Second-generation antipsychotics are typically first-line, chosen by symptom profile and side-effect tolerance.
- Long-acting injectables reduce relapse for people who have trouble taking daily medication.
- Clozapine is uniquely effective after two failed antipsychotic trials and lowers suicide risk, with required blood monitoring.
Frequently Asked Questions
What's the difference between first- and second-generation antipsychotics?
First-generation antipsychotics (haloperidol, chlorpromazine) carry higher rates of extrapyramidal symptoms and tardive dyskinesia. Second-generation agents have lower motor side-effect risk but carry metabolic risk (weight, glucose, lipids). Selection depends on symptom profile and side-effect tolerability.
When is clozapine indicated?
Clozapine is uniquely effective for treatment-resistant schizophrenia (failure of two adequate antipsychotic trials) and reduces suicide risk. It requires monitoring for agranulocytosis, myocarditis, and metabolic effects but should not be delayed once criteria are met.
What about long-acting injectables?
LAI antipsychotics dramatically reduce relapse in patients with adherence difficulty and are increasingly used earlier in the illness course. Options include aripiprazole, paliperidone, olanzapine, and risperidone in various dosing intervals.